Symbiotec Pharmalab shares surged 7.4% to ₹1,250 after Motilal Oswal issued a buy rating, citing a ₹1,430 target and 23% upside. The move followed the company’s FY26 results, where revenue hit ₹870 cr, EBITDA ₹240 cr and PAT ₹110 cr, all rising 15%, 51% and 69% YoY respectively.
The 15% revenue growth eclipses the median analyst estimate of ₹800 cr, while EBITDA and PAT outpace the ₹200 cr and ₹90 cr forecasts by 20% and 22%. The jump underscores a 33% CAGR projection for FY26‑29, pushing revenue to ₹2,030 cr, EBITDA to ₹560 cr and PAT to ₹300 cr, driven by expanding CDMO and injectable operations.
Motilal Oswal values the stock at 35‑times its 12‑month forward earnings, arriving at a ₹1,430 target. In a bull‑case scenario, a 38‑x PE would lift the target to ₹1,690, while a bear‑case 31‑x PE trims it to ₹1,000, reflecting risks of delayed capacity ramp‑up and competitive pressure. The stock is currently trading 4.6% higher at ₹1,218.
The company’s integrated platform – from steroid API to precision fermentation – positions it in a $800 m corticosteroid market and a $92 bn fermentation‑based TAM. Analysts note that strong customer relationships, regulatory credentials and forward‑integration into double‑chamber vials should sustain margin expansion, but geographic concentration of manufacturing sites remains a concern.
Market watchers will eye the upcoming guidance on CDMO contracts in Q1 2027 and the company’s ability to hit its FY29 targets. With shares already up 23% from issue price, traders are gauging whether the 23% upside will hold or if the 45% bull‑case target is reachable.